IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Terrill K. McClanahan, Jared Lunceford et al.|Journal of Clinical Investigation|2017Cited by 3.9k
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyRăzvan Cristescu, David R. Kaufman, Robin Mogg et al.|Science|2018Cited by 2.3k
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Farid El-Hajbi et al.|JAMA Oncology|2018Cited by 518
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I. Haddad, Ranee Mehra, Tanguy Y. Seiwert et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 96
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G. Pfister, Joshua Bauml, Robert I. Haddad et al.|Cancer Medicine|2022Cited by 48